Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04372277 · ClinicalTrials.gov registry record · Phase 4
Taltz in Combination With Enstilar for Psoriasis
A Phase 4 study of Psoriasis, sponsored by Psoriasis Treatment Center of Central New Jersey.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT04372277: Recruiting Phase 4 study of Psoriasis, sponsored by Psoriasis Treatment Center of Central New Jersey.
NCT04372277 is a Phase 4 study of Psoriasis that is actively recruiting participants, run by Psoriasis Treatment Center of Central New Jersey. The registered enrollment target is 25 participants, below the 489-participant average among 125 other Psoriasis trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04372277, a Phase 4 study of Psoriasis, is actively recruiting participants, sponsored by Psoriasis Treatment Center of Central New Jersey.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
Enstilar in combination with Taltz for plaque psoriasis.
Primary Outcome
Body surface area where 1 palm is equivalent to 1%. Endpoint will evaluate number of patiens who achieve body surface are 0 or 1.
Conditions Studied
Interventions
- DRUG Enstilar
Study Locations (1)
New Jersey
- Psoriasis Treatment Center of Central New Jersey - East Windsor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2020-04-28 |
| Est. Completion | 2021-03-30 |
| Phase | Phase 4 |
What NCT04372277 shows while recruiting
NCT04372277 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 489-participant average among 125 other Psoriasis trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Psoriasis appearing as the primary indexed condition, and to 1 intervention - of which Enstilar is the first listed.
NCT04372277 reports a single indexed study location in New Jersey.
Frequently Asked Questions
What is clinical trial NCT04372277 about?
NCT04372277 is a clinical study titled "Taltz in Combination With Enstilar for Psoriasis". Enstilar in combination with Taltz for plaque psoriasis.
What is the current status of trial NCT04372277?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 25 participants. The study started on 2020-04-28. Estimated completion is 2021-03-30.
What conditions does trial NCT04372277 study?
This clinical trial studies the following conditions: Psoriasis.
What interventions are being tested in trial NCT04372277?
The interventions under investigation include: Enstilar (DRUG).
Who is sponsoring clinical trial NCT04372277?
This trial is sponsored by Psoriasis Treatment Center of Central New Jersey, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04372277 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04372277's enrollment target sits among peer trials
25 102nd of 125 higher than 22 of 125 other Psoriasis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Psoriasis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Duobrii in Combination With Biologics
RECRUITING · Phase 4
-
Development of Predictive Psoriasis Response Endotypes Using Single Cell Transcriptomics
RECRUITING · Phase 4
-
ILUMYA in Combination With HALOG Ointment 0.1% for Plaque Psoriasis.
RECRUITING · Phase 4
-
A Safety and Pharmacokinetics Study of IDP-122 Lotion in Pediatric Participants With Plaque Psoriasis
RECRUITING · Phase 4
-
A Safety and Pharmacokinetics Study of IDP-118 Lotion in Pediatric Participants With Plaque Psoriasis
RECRUITING · Phase 4
-
A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI